RxDoctor Payments Data

Frank Puhalovich, MD

Neurology · Cumming, GANPI 1548253941

Payments from drug & device makers

$32,658in general payments, 2019–2025

Across 1,815 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$2K
  • Biogen$2K
  • Pfizer$1K
  • Acadia Pharmaceuticals Inc$1K
  • Eisai Inc.$1K
  • plus $21K from 54 others

What the payments were for

  • Speaking & faculty fees$600%
  • Food & beverage$32,46699%
  • Education$1320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)285$3,612
UCB, Inc.88$1,961
Biogen97$1,688
Pfizer99$1,411
Acadia Pharmaceuticals Inc73$1,296
Eisai Inc.61$1,265
Lundbeck LLC47$1,177
Novartis74$1,143
Neurocrine Biosciences, Inc.55$1,085
EMD Serono, Inc.64$1,058
MDD US Operations, LLC35$971
Lilly USA, LLC48$931
AstraZeneca(2 entities)38$914
Sunovion Pharmaceuticals Inc.59$884
Avanir Pharmaceuticals, Inc.43$812
Teva Pharmaceuticals USA, Inc.55$760
Amgen(2 entities)31$749
Jazz Pharmaceuticals Inc.28$686
Sanofi31$603
Otsuka America Pharmaceutical, Inc.26$583
Supernus Pharmaceuticals, Inc.52$577
Biohaven Pharmaceuticals, Inc.32$528
Biohaven Pharmaceutical Holding Company Ltd.27$414
Catalyst Pharmaceuticals, Inc.15$414
Amneal Pharmaceuticals LLC23$384
Adamas Pharmaceuticals, Inc.22$373
Kyowa Kirin, Inc.21$373
Argenx US, Inc.14$366
Johnson & Johnson(2 entities)16$342
CSL Behring15$327
Sumitomo Pharma America, Inc.13$321
Mallinckrodt Hospital Products Inc.14$262
Bristol Myers Squibb8$255
Impel Pharmaceuticals Inc.14$234
Acorda Therapeutics, Inc9$234
Harmony Biosciences LLC10$231
Ipsen Biopharmaceuticals, Inc11$229
Grifols USA, LLC10$201
Bausch Health US, LLC10$199
Axsome Therapeutics, Inc.7$196
Neurelis, Inc.8$188
Upsher-smith Laboratories LLC10$176
Azurity Pharmaceuticals, Inc.8$151
Currax Pharmaceuticals LLC9$126
Aprecia Pharmaceuticals, LLC6$122
Genentech USA, Inc.6$121
Avion Pharmaceuticals7$113
Takeda Pharmaceuticals U.S.A., Inc.4$105
Cycle Pharmaceuticals Inc3$92
Forte Bio-pharma LLC4$88
Vertical Pharmaceuticals, LLC5$82
Scilex Pharmaceuticals Inc.4$80
Boston Scientific4$79
SK Life Science, Inc.4$78
Mallinckrodt Enterprises LLC4$75
Vanda Pharmaceuticals Inc.2$71
Banner Life Sciences, LLC3$67
Corium, LLC3$63
Greenwich Biosciences, Inc.3$63
Arbor Pharmaceuticals, Inc.3$60

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,658 in reported general payments places this provider in the 85th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$773,840
Medicare patients
811
Services billed
374,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4626$386,211
VumerityDiroximel Fumarate33$323,179
IngrezzaValbenazine Tosylate23$199,120
NuplazidPimavanserin Tartrate26$126,749
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$125,130
CopaxoneGlatiramer Acetate14$81,668
UbrelvyUbrogepant51$81,158
Aimovig AutoinjectorErenumab-Aooe85$67,303
XadagoSafinamide Mesylate29$56,062
Emgality PenGalcanezumab-Gnlm60$54,148
Nurtec OdtRimegepant Sulfate27$47,913
NeuproRotigotine33$40,813
NourianzIstradefylline11$40,006
BotoxOnabotulinumtoxina32$39,063
EliquisApixaban35$32,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$1,688$323,17933 claims
Neurocrine Biosciences, Inc.Ingrezza$1,085$199,12023 claims
AbbVieUbrelvy, Botox, Qulipta$3,612$151,598110 claims
Acadia Pharmaceuticals IncNuplazid$1,296$126,74926 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$105$125,13012 claims
Teva Pharmaceuticals USA, Inc.Copaxone$760$81,66814 claims
PfizerNurtec Odt, Eliquis$1,411$80,48462 claims
UCB, Inc.Neupro$1,961$40,81333 claims
Kyowa Kirin, Inc.Nourianz$373$40,00611 claims
Avanir Pharmaceuticals, Inc.Nuedexta$812$22,84221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 506 neurology providers in Georgia.

Other neurology in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →